Aspirin and immune boosters could help fight prostate cancer before surgery

NCT ID NCT03899987

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether giving a combination of enteric-coated aspirin, rintatolimod, and interferon-alpha 2b before prostate cancer surgery can boost the immune system's attack on tumors. The study involves 12 men with localized prostate cancer who are scheduled for surgery. The main goal is to see if these drugs increase cancer-fighting immune cells in the tumor.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
enteric-coated aspirin, rintatolimod, and interferon-alpha 2b
What this could lead to
If successful, this could point toward a new pre-surgery treatment that helps the immune system fight prostate cancer and lowers the chance of it coming back.
What could go wrong
This is a very small early-phase trial with only 12 participants, so results may not apply broadly. The drugs may cause side effects like flu-like symptoms or bleeding risks from aspirin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.